Novel Clinical Practice Assessments: Informational Statements by the Musculoskeletal Tumor Society
- PMID: 39463163
- PMCID: PMC12065448
- DOI: 10.1002/jso.27967
Novel Clinical Practice Assessments: Informational Statements by the Musculoskeletal Tumor Society
Abstract
Musculoskeletal oncology involves rare diseases. As a result, there is a paucity of literature to guide practitioners. Studies are often clinical experience, retrospective reviews, noncomparative studies, and involve small numbers of patients. However, technological advances consistently arise in this field. This article represents the Musculoskeletal Tumor Society efforts to improve multispecialty collaboration and research credibility. It involves brief systematic reviews of novel ideas and suggests high-quality research needed to provide and standardize best practices within this field.
Keywords: MSTS; clinical practice; evidence‐based; novel; review.
© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.
Conflict of interest statement
Nicholas Tedesco – Doctorpedia: Stock or stock Options. Journal of the American Osteopathic Academy of Orthopedics: Editorial board. Sanara MedTech: Publishing royalties, financial or material support. Musculoskeletal Tumor Society: Board or committee member. American Academy of Orthopedic Surgeons: Board or committee member. RomTech Inc.: Stock or stock Options. Matthew Wallace – Nothing to disclose. Yee‐Cheen Doung – Musculoskeletal Tumor Society: Board or committee member. Matthew Colman – Alphatec Spine: IP royalties; Paid consultant. AO Spine North America: Board or committee member; Research support. Cervical Spine Research Society: Board or committee member. Musculoskeletal Tumor Society: Board or committee member. CSRS: Research support. DePuy, A Johnson & Johnson Company: Paid presenter or speaker. K2M: Paid presenter or speaker. K2M/Stryker Spine: Paid consultant. LSRS: Board or committee member. Musculoskeletal Tumor Society: Board or committee member. North American Spine Society: Board or committee member. Orthofix: Paid consultant. Orthofix Inc.: Paid presenter or speaker. Spinal Elements: IP royalties; Paid consultant. Xenix Medical: Paid consultant. Felasfa Wodajo – Onkos Surgical: Paid consultant. Musculoskeletal Tumor Society: Board or committee member.
References
-
- Wright C. N., “Federal Research and Development: Funding Has Grown Since 2012 and Is Concentrated Within a Few Agencies, Congress A to Z ‐ Government Accountability Office,” 2022. pp. 1–60, http://www.gao.gov/products/gao-23-105396.
-
- RePORT: Research Portfolio Online Tools . National Institutes of Health, U.S. Department of Health and Human Services, 2024.
-
- Prabhu Das I., Baker M., Altice C., Castro K. M., Brandys B., and Mitchell S. A., “Outcomes of Multidisciplinary Treatment Planning in Us Cancer Care Settings,” Cancer 124, no. 18 (2018): 3656–3667. - PubMed
-
- West R. B., Rubin B. P., Miller M. A., et al., “A Landscape Effect in Tenosynovial Giant Cell Tumor From Activation of CSF‐1 Expression By a Translocation in a Minority of Tumor Cells,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 3 (2006): 690–695. - PMC - PubMed
-
- Stacchiotti S., Dürr H. R., Schaefer I. M., et al., “Best Clinical Management of Tenosynovial Giant Cell Tumour (Tgct): A Consensus Paper From the Community of Experts,” Cancer Treatment Reviews 112 (2023): 102491. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials